Skip to main content

Browse All Resources

Featured Downloadable Resources

EGFR-Driven Solid Tumors Preclinical Data Thumbnail
Infographic

EGFR-Driven Solid Tumors Preclinical Data
EGFR-Mutated NSCLC: Acquired Resistance Thumbnail
Infographic

EGFR-Mutated NSCLC: Acquired Resistance
Top 5 Highlights From ELCC 2026 Thumbnail
Infographic

Top 5 Highlights From ELCC 2026

Filter Resources

Downloadable Resources Only
All
Videos
Articles
Infographics
No Results Found. Please Try Adjusting Filters
Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC
Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLCNews & Conference Highlights

Silevertinib Yields Significant Response Rates in Frontline EGFR Non-Classically–Mutated NSCLC

June 3, 2026
ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases
ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain MetastasesNews & Conference Highlights

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases

June 3, 2026
DZD6008 Demonstrates Salvage Potential in EGFR C797X–Mutant NSCLC
DZD6008 Demonstrates Salvage Potential in EGFR C797X–Mutant NSCLCNews & Conference Highlights

DZD6008 Demonstrates Salvage Potential in EGFR C797X–Mutant NSCLC

June 2, 2026
Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC
EGFR+ NSCLC | Image Credit: © Image by Ashling Wahner & MJH Life Sciences Using AI
Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLCEGFR Sanity Import

Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

June 1, 2026
Sequential Erlotinib Plus Ramucirumab Prior to Osimertinib Fails to Improve Outcomes in EGFR L858R–Mutant NSCLC
Sequential Erlotinib Plus Ramucirumab Prior to Osimertinib Fails to Improve Outcomes in EGFR L858R–Mutant NSCLCNews & Conference Highlights

Sequential Erlotinib Plus Ramucirumab Prior to Osimertinib Fails to Improve Outcomes in EGFR L858R–Mutant NSCLC

June 1, 2026
FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC
FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLCNews & Conference Highlights

FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

June 1, 2026
Sunvozertinib Shows Superior Efficacy vs Chemo in Frontline Advanced EGFR Exon 20+ NSCLC
Sunvozertinib Shows Superior Efficacy vs Chemo in Frontline Advanced EGFR Exon 20+ NSCLCNews & Conference Highlights

Sunvozertinib Shows Superior Efficacy vs Chemo in Frontline Advanced EGFR Exon 20+ NSCLC

May 30, 2026
Amivantamab Plus Lazertinib Produces Clinically Meaningful OS in Atypical EGFR-Mutated Advanced NSCLC
Amivantamab Plus Lazertinib Produces Clinically Meaningful OS in Atypical EGFR-Mutated Advanced NSCLCNews & Conference Highlights

Amivantamab Plus Lazertinib Produces Clinically Meaningful OS in Atypical EGFR-Mutated Advanced NSCLC

May 29, 2026
Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLC
Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLCExpert Insights

Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLC

May 11, 2026
Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance
Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS SurveillanceExpert Insights

Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance

May 11, 2026
Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging EvidenceExpert Insights

Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

May 11, 2026
MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management
MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity ManagementExpert Insights

MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management

May 11, 2026
Second-Line Regimen Choice and Re-Biopsy Realities in EGFR-Mutant NSCLC After Osimertinib
Second-Line Regimen Choice and Re-Biopsy Realities in EGFR-Mutant NSCLC After OsimertinibExpert Insights

Second-Line Regimen Choice and Re-Biopsy Realities in EGFR-Mutant NSCLC After Osimertinib

May 11, 2026
Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC
Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLCExpert Insights

Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC

May 11, 2026
Sequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later Options
Sequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later OptionsExpert Insights

Sequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later Options

May 11, 2026
Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life
Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of LifeExpert Insights

Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life

May 11, 2026
EGFR-Driven Solid Tumors Preclinical Data
EGFR-Driven Solid Tumors Preclinical DataNews & Conference Highlights

EGFR-Driven Solid Tumors Preclinical Data

May 7, 2026
HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance
HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI ResistanceNews & Conference Highlights

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

May 6, 2026
EGFR-Mutated NSCLC: Acquired Resistance
EGFR-Mutated NSCLC: Acquired ResistanceNews & Conference Highlights

EGFR-Mutated NSCLC: Acquired Resistance

May 6, 2026
Top 5 Highlights From ELCC 2026
Top 5 Highlights From ELCC 2026News & Conference Highlights

Top 5 Highlights From ELCC 2026

May 4, 2026
EGFR-Mutated NSCLC Frontline Treatment
EGFR-Mutated NSCLC Frontline TreatmentNews & Conference Highlights

EGFR-Mutated NSCLC Frontline Treatment

May 4, 2026
Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC
Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLCNews & Conference Highlights

Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC

May 4, 2026
VRN110755 in EGFR-Mutant NSCLC
VRN110755 in EGFR-Mutant NSCLCNews & Conference Highlights

VRN110755 in EGFR-Mutant NSCLC

May 4, 2026
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line TreatmentHow I Treat

EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

April 28, 2026
EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy
EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination TherapyHow I Treat

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy

April 28, 2026
Chemotherapy (chemo) Rechallenge in Patients (pts) With Egfr-mutated (EGFRm) Advanced NSCLC Who Discontinued 1L Osimertinib (osi) + Platinum–pemetrexed (plat-pem) Due to Progression (PD): FLAURA2 Exploratory Analysis
Chemotherapy (chemo) Rechallenge in Patients (pts) With Egfr-mutated (EGFRm) Advanced NSCLC Who Discontinued 1L Osimertinib (osi) + Platinum–pemetrexed (plat-pem) Due to Progression (PD): FLAURA2 Exploratory AnalysisNews & Conference Highlights

Chemotherapy (chemo) Rechallenge in Patients (pts) With Egfr-mutated (EGFRm) Advanced NSCLC Who Discontinued 1L Osimertinib (osi) + Platinum–pemetrexed (plat-pem) Due to Progression (PD): FLAURA2 Exploratory Analysis

April 27, 2026
Osimertinib (osi) With or Without Chemotherapy (CTx) as First-line Treatment in EGFR-mutant (EGFRm) Advanced NSCLC With Concurrent TP53 Mutations (TOP Study)
Osimertinib (osi) With or Without Chemotherapy (CTx) as First-line Treatment in EGFR-mutant (EGFRm) Advanced NSCLC With Concurrent TP53 Mutations (TOP Study)News & Conference Highlights

Osimertinib (osi) With or Without Chemotherapy (CTx) as First-line Treatment in EGFR-mutant (EGFRm) Advanced NSCLC With Concurrent TP53 Mutations (TOP Study)

April 24, 2026
SC3613 Shows Potent Anti-Tumor Activity and Potential for Tolerable Safety in EGFR-Mutant NSCLC Cells
SC3613 Shows Potent Anti-Tumor Activity and Potential for Tolerable Safety in EGFR-Mutant NSCLC CellsNews & Conference Highlights

SC3613 Shows Potent Anti-Tumor Activity and Potential for Tolerable Safety in EGFR-Mutant NSCLC Cells

April 23, 2026
Preclinical Data for EPI-326 Support Clinical Research in EGFR-Responsive Solid Tumors
Preclinical Data for EPI-326 Support Clinical Research in EGFR-Responsive Solid TumorsNews & Conference Highlights

Preclinical Data for EPI-326 Support Clinical Research in EGFR-Responsive Solid Tumors

April 23, 2026
Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC
Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLCNews & Conference Highlights

Amivantamab Plus Lazertinib Extends Second-Line PFS in EGFR-Mutant Advanced NSCLC

April 23, 2026
VRN110755 Shows Initial Antitumor Activity Across Dose Levels in EGFR-Mutant NSCLC
VRN110755 Shows Initial Antitumor Activity Across Dose Levels in EGFR-Mutant NSCLCNews & Conference Highlights

VRN110755 Shows Initial Antitumor Activity Across Dose Levels in EGFR-Mutant NSCLC

April 22, 2026
ABK-EGFR-1 Displays Preclinical Activity in EGFR C797S–Driven Xenograft Models
ABK-EGFR-1 Displays Preclinical Activity in EGFR C797S–Driven Xenograft ModelsNews & Conference Highlights

ABK-EGFR-1 Displays Preclinical Activity in EGFR C797S–Driven Xenograft Models

April 22, 2026
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved CaseHow I Treat

EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case

April 21, 2026
EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment Evaluation
EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment EvaluationHow I Treat

EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment Evaluation

April 21, 2026
Future Directions and Unmet Needs in in EGFR-Mutant NSCLC
Future Directions and Unmet Needs in in EGFR-Mutant NSCLCHow I Treat

Future Directions and Unmet Needs in in EGFR-Mutant NSCLC

April 21, 2026
Structure-Function–Based Classification System Could Refine TKI Selection for Atypical EGFR-Mutant NSCLC Subsets
Structure-Function–Based Classification System Could Refine TKI Selection for Atypical EGFR-Mutant NSCLC SubsetsNews & Conference Highlights

Structure-Function–Based Classification System Could Refine TKI Selection for Atypical EGFR-Mutant NSCLC Subsets

April 20, 2026
Future Directions: Toward Personalized EGFR Therapy in NSCLC
Future Directions: Toward Personalized EGFR Therapy in NSCLCExpert Insights

Future Directions: Toward Personalized EGFR Therapy in NSCLC

April 20, 2026
ctDNA and Real-World Data Guide Strategies to Overcome Acquired Resistance in EGFR-Mutated NSCLC
ctDNA and Real-World Data Guide Strategies to Overcome Acquired Resistance in EGFR-Mutated NSCLCNews & Conference Highlights

ctDNA and Real-World Data Guide Strategies to Overcome Acquired Resistance in EGFR-Mutated NSCLC

April 16, 2026
Unpacking the Advantages and Limitations of Leading Frontline Regimens in EGFR-Mutated NSCLC
Unpacking the Advantages and Limitations of Leading Frontline Regimens in EGFR-Mutated NSCLCNews & Conference Highlights

Unpacking the Advantages and Limitations of Leading Frontline Regimens in EGFR-Mutated NSCLC

April 15, 2026
MET TKIs and ADCs May Broaden Post-Osimertinib Treatment Options in EGFR-Mutant NSCLC
MET TKIs and ADCs May Broaden Post-Osimertinib Treatment Options in EGFR-Mutant NSCLCNews & Conference Highlights

MET TKIs and ADCs May Broaden Post-Osimertinib Treatment Options in EGFR-Mutant NSCLC

April 14, 2026
Building a Sequencing Roadmap at Diagnosis in EGFR-Mutant NSCLC
Building a Sequencing Roadmap at Diagnosis in EGFR-Mutant NSCLCHow I Treat

Building a Sequencing Roadmap at Diagnosis in EGFR-Mutant NSCLC

April 14, 2026
EGFR-Mutated NSCLC: Emerging Role of TROP2-Directed Antibody–Drug Conjugates
EGFR-Mutated NSCLC: Emerging Role of TROP2-Directed Antibody–Drug ConjugatesHow I Treat

EGFR-Mutated NSCLC: Emerging Role of TROP2-Directed Antibody–Drug Conjugates

April 14, 2026
Integrating ADCs Into the Treatment Paradigm in in EGFR-Mutant NSCLC
Integrating ADCs Into the Treatment Paradigm in in EGFR-Mutant NSCLCHow I Treat

Integrating ADCs Into the Treatment Paradigm in in EGFR-Mutant NSCLC

April 14, 2026
EGFR-Mutated NSCLC: Integrating Emerging ELCC Data Into Treatment Sequencing
EGFR-Mutated NSCLC: Integrating Emerging ELCC Data Into Treatment SequencingHow I Treat

EGFR-Mutated NSCLC: Integrating Emerging ELCC Data Into Treatment Sequencing

April 14, 2026
Breaking the “Undruggable” Barrier in EGFR Exon 20 Insertion+ NSCLC
Breaking the “Undruggable” Barrier in EGFR Exon 20 Insertion+ NSCLCNews & Conference Highlights

Breaking the “Undruggable” Barrier in EGFR Exon 20 Insertion+ NSCLC

April 13, 2026
The Emerging Role of ADCs in EGFR-Mutant NSCLC
The Emerging Role of ADCs in EGFR-Mutant NSCLCExpert Insights

The Emerging Role of ADCs in EGFR-Mutant NSCLC

April 13, 2026
Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC
Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLCExpert Insights

Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC

April 13, 2026
Emerging TKIs Drive Renewed Progress in EGFR Exon 20 Insertion–Positive NSCLC
Emerging TKIs Drive Renewed Progress in EGFR Exon 20 Insertion–Positive NSCLCNews & Conference Highlights

Emerging TKIs Drive Renewed Progress in EGFR Exon 20 Insertion–Positive NSCLC

April 10, 2026
EGFR-Mutated NSCLC: Impact of Subcutaneous Administration on Treatment Experience
EGFR-Mutated NSCLC: Impact of Subcutaneous Administration on Treatment ExperienceHow I Treat

EGFR-Mutated NSCLC: Impact of Subcutaneous Administration on Treatment Experience

April 7, 2026
Impact of Co-Mutations on Treatment Strategies in EGFR-Mutant NSCLC
Impact of Co-Mutations on Treatment Strategies in EGFR-Mutant NSCLCHow I Treat

Impact of Co-Mutations on Treatment Strategies in EGFR-Mutant NSCLC

April 7, 2026
The Role of Chemotherapy Rechallenge in EGFR-Mutant NSCLC
The Role of Chemotherapy Rechallenge in EGFR-Mutant NSCLCHow I Treat

The Role of Chemotherapy Rechallenge in EGFR-Mutant NSCLC

April 7, 2026
EGFR-Mutated NSCLC: Risk–Benefit Assessment in First-Line Treatment Decisions
EGFR-Mutated NSCLC: Risk–Benefit Assessment in First-Line Treatment DecisionsHow I Treat

EGFR-Mutated NSCLC: Risk–Benefit Assessment in First-Line Treatment Decisions

April 7, 2026
Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC
Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLCExpert Insights

Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC

April 6, 2026
Rethinking High-Risk EGFR-Mutant NSCLC
Rethinking High-Risk EGFR-Mutant NSCLCExpert Insights

Rethinking High-Risk EGFR-Mutant NSCLC

April 6, 2026
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After ProgressionNews & Conference Highlights

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression

April 2, 2026
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Navigating Second-Line Treatment Decisions in EGFR+ NSCLCExpert Insights

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC

April 1, 2026
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLCNews & Conference Highlights

Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC

March 30, 2026
Interpreting FLAURA2 for Sequencing Strategies in EGFR-Mutant NSCLC
Interpreting FLAURA2 for Sequencing Strategies in EGFR-Mutant NSCLCHow I Treat

Interpreting FLAURA2 for Sequencing Strategies in EGFR-Mutant NSCLC

March 30, 2026
Frontline Decision-Making in EGFR-Mutant NSCLC
Frontline Decision-Making in EGFR-Mutant NSCLCHow I Treat

Frontline Decision-Making in EGFR-Mutant NSCLC

March 30, 2026
EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy
EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line TherapyHow I Treat

EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy

March 30, 2026
EGFR-Mutated NSCLC: Evolving First-Line Treatment Landscape
EGFR-Mutated NSCLC: Evolving First-Line Treatment LandscapeHow I Treat

EGFR-Mutated NSCLC: Evolving First-Line Treatment Landscape

March 30, 2026
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLCExpert Insights

Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC

March 30, 2026
The Future of EGFR+ NSCLC Management
The Future of EGFR+ NSCLC ManagementExpert Insights

The Future of EGFR+ NSCLC Management

March 30, 2026
The Evolution of Frontline Therapy in EGFR-Mutant NSCLC
The Evolution of Frontline Therapy in EGFR-Mutant NSCLCExpert Insights

The Evolution of Frontline Therapy in EGFR-Mutant NSCLC

March 30, 2026
Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC
Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLCNews & Conference Highlights

Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC

March 27, 2026
Breakthrough in Pretreated EGFR-Mutated NSCLC
Breakthrough in Pretreated EGFR-Mutated NSCLCNews & Conference Highlights

Breakthrough in Pretreated EGFR-Mutated NSCLC

March 27, 2026
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLCNews & Conference Highlights

Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC

March 27, 2026
Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC
Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLCNews & Conference Highlights

Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC

March 26, 2026
Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC
Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLCNews & Conference Highlights

Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC

March 26, 2026
Adding Local Consolidative Therapy (LCT) to Osimertinib Significantly Improves PFS in EGFR-Mutated NSCLC
Adding Local Consolidative Therapy (LCT) to Osimertinib Significantly Improves PFS in EGFR-Mutated NSCLCNews & Conference Highlights

Adding Local Consolidative Therapy (LCT) to Osimertinib Significantly Improves PFS in EGFR-Mutated NSCLC

March 26, 2026
Osimertinib + Chemotherapy Doubles Progression-Free Survival in High-Risk NSCLC
Osimertinib + Chemotherapy Doubles Progression-Free Survival in High-Risk NSCLCNews & Conference Highlights

Osimertinib + Chemotherapy Doubles Progression-Free Survival in High-Risk NSCLC

March 26, 2026
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLCExpert Insights

How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC

March 26, 2026
Promoting Treatment Adherence and Managing AEs in EGFR+ NSCLC
Promoting Treatment Adherence and Managing AEs in EGFR+ NSCLCExpert Insights

Promoting Treatment Adherence and Managing AEs in EGFR+ NSCLC

March 23, 2026
Where ADCs Fit in the EGFR+ NSCLC Treatment Paradigm
Where ADCs Fit in the EGFR+ NSCLC Treatment ParadigmExpert Insights

Where ADCs Fit in the EGFR+ NSCLC Treatment Paradigm

March 23, 2026
Sequencing Considerations After the MARIPOSA or FLAURA-2 Regimens in EGFR+ NSCLC
Sequencing Considerations After the MARIPOSA or FLAURA-2 Regimens in EGFR+ NSCLCExpert Insights

Sequencing Considerations After the MARIPOSA or FLAURA-2 Regimens in EGFR+ NSCLC

March 16, 2026
Sequencing in EGFR+ NSCLC: How MET Amplifications and Other Factors Guide Decisions
Sequencing in EGFR+ NSCLC: How MET Amplifications and Other Factors Guide DecisionsExpert Insights

Sequencing in EGFR+ NSCLC: How MET Amplifications and Other Factors Guide Decisions

March 16, 2026
Ongoing Research to Watch in EGFR-Mutated NSCLC
Ongoing Research to Watch in EGFR-Mutated NSCLCExpert Insights

Ongoing Research to Watch in EGFR-Mutated NSCLC

March 13, 2026
Experiences With ADCs in EGFR-Mutated NSCLC Management
Experiences With ADCs in EGFR-Mutated NSCLC ManagementExpert Insights

Experiences With ADCs in EGFR-Mutated NSCLC Management

March 13, 2026
Remaining Evidence Gaps in EGFR-Mutated NSCLC Care
Remaining Evidence Gaps in EGFR-Mutated NSCLC CareExpert Insights

Remaining Evidence Gaps in EGFR-Mutated NSCLC Care

March 13, 2026
Resistance Mechanisms in EGFR-Mutated NSCLC
Resistance Mechanisms in EGFR-Mutated NSCLCExpert Insights

Resistance Mechanisms in EGFR-Mutated NSCLC

March 13, 2026
Evolving Frontline Treatment Options in EGFR-Mutated NSCLC
Evolving Frontline Treatment Options in EGFR-Mutated NSCLCExpert Insights

Evolving Frontline Treatment Options in EGFR-Mutated NSCLC

March 13, 2026
Sequencing Considerations in Advanced EGFR-Mutated NSCLC
Sequencing Considerations in Advanced EGFR-Mutated NSCLCExpert Insights

Sequencing Considerations in Advanced EGFR-Mutated NSCLC

March 13, 2026
Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLC
Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLCExpert Insights

Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLC

March 13, 2026
Determining When to Utilize Combination Approaches in EGFR+ NSCLC
Determining When to Utilize Combination Approaches in EGFR+ NSCLCExpert Insights

Determining When to Utilize Combination Approaches in EGFR+ NSCLC

March 11, 2026
Factors Driving Treatment Decision-Making in Frontline EGFR+ NSCLC
Factors Driving Treatment Decision-Making in Frontline EGFR+ NSCLCExpert Insights

Factors Driving Treatment Decision-Making in Frontline EGFR+ NSCLC

March 11, 2026
Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC
Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLCExpert Insights

Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC

March 6, 2026
How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC
How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLCExpert Insights

How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC

March 6, 2026
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLCExpert Insights

AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC

February 27, 2026
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC ManagementExpert Insights

The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management

February 27, 2026
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk FeaturesExpert Insights

Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features

February 20, 2026
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLCExpert Insights

Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC

February 20, 2026
Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC
Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLCNews & Conference Highlights

Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC

December 22, 2025
FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLC
FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLCNews & Conference Highlights

FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLC

December 18, 2025
EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies
EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L StrategiesExpert Insights

EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies

December 3, 2025
EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient Factors
EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient FactorsExpert Insights

EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient Factors

December 3, 2025
EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination Therapy
EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination TherapyExpert Insights

EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination Therapy

December 3, 2025
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MScEmerging Voices in EGFR Care

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

November 14, 2025
NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease
NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated DiseaseNews & Conference Highlights

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

November 10, 2025
Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC
Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLCNews & Conference Highlights

Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC

October 29, 2025
FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC
FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLCExpert Insights

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

October 27, 2025

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

© 2026 MJH Life Sciences. All rights reserved.

Home
Clinical Updates Calendar
View All Resources